novartis
- 网络诺华;诺华公司;诺华制药;瑞士诺华
-
The treatment is made by Novartis and is called Kymriah .
该疗法由诺华公司研发,并被命名为Kymriah。
-
His office building for the health care company Novartis in Shanghai is under construction .
阿拉维纳为药企诺华(Novartis)在上海设计的办公楼正在建设之中。
-
Novartis is taking a different route through drugs that treat smaller patient populations .
而诺华公司致力于针对患者人群较小的药物,走了一条截然不同的道路。
-
Swiss drug firm Novartis acquired the rights to market the therapy outside China in1994 .
1994年,瑞士药厂诺华买走了复方蒿甲醚在中国以外市场的销售权。
-
Dr Diagana says that Novartis and its partners are moving as fast as possible .
迪亚贾纳博士表示,诺华及其合作伙伴正尽快采取行动。
-
But Mr Fishman said Novartis selected Shanghai because of the potential strength of scientific talent .
不过,费思民表示,诺华选择上海,是因为上海科技人才的潜在实力。
-
Dr Diagana says Novartis aims to have at least one of them on the market by 2021 .
迪亚贾纳博士表示,诺华计划最迟在2021年至少向市场投放其中一种药物。
-
But Novartis has decided re-think the methodology behind drug development , Jimenez says .
而江慕忠表示,诺华公司决定重新考虑药物开发方案。
-
None of the Chinese universities is particularly famous , but Novartis believes their standards are already world-class .
没有一所中国大学特别驰名,但诺华认为这些大学的标准业已达到世界水平。
-
Novartis moved its research base from Basel to Cambridge , Massachusetts , in 2004 .
诺华制药于2004年把研发基地从巴塞尔迁至美国马萨诸塞州的剑桥。
-
In a 2014 study by the drug company Novartis , the drug appeared to bolster the immune system in older patients .
制药公司诺华(Novartis)在2014年进行的一项研究显示,它似乎可以增强老年病人的免疫系统。
-
According to a February analyst report from Morningstar , Novartis is well positioned for good long-term growth .
晨星公司(Morningstar)二月份的分析师报告显示,诺华公司具备长期良性发展的条件。
-
HSBC declined to comment and Novartis did not respond .
汇丰拒绝置评,而诺华未做回应。
-
Novartis has opted for diversification to reduce the uncertainties in developing of patented drugs .
诺华(Novartis)选择通过多样化经营,来降低开发专利药的不确定性。
-
Studies have shown that 83 percent of patients responded to the treatment , achieving remission within three months , Novartis said .
诺华称,研究发现,治疗对83%的患者有效,患者的病情在三个月内成功得到了缓解。
-
Voltaren Gel was shown to cut pain in knee and hand osteoarthritis , states Novartis .
研究结果显示,扶他林乳胶剂对膝盖和手性关节疼痛有阻断作用。
-
Novartis has opened a research centre in Shanghai and has another outpost in Singapore focused on tropical diseases .
诺华制药已经在上海建立了一个科研中心,另外,诺华还在新加波开设了一家热带疾病研究所。
-
But , moving beyond the eye , Novartis is clearly a leader globally in a number of therapeutic areas .
不过,除了眼科,诺华在众多临床治疗领域都是全球领导者。
-
Proof-of-concept data are expected soon on a second Novartis compound , known as KAF 156 .
预计诺华的第二种复方药物(名为KAF156)的概念验证数据将很快出炉。
-
Novartis said the Indian clause violated the Trade Related Intellectual Property Rights ( TRIPS ) rules under the World Trade Organization .
诺华说印度专利法的该条款违反了世界贸易组织的《与贸易有关的知识产权协定》(TRIPS)。
-
Novartis ( NVS ) has a new strategy to try to generate that kind of serendipity .
诺华公司新策略的目的就是找到这种意外的惊喜。
-
The old model where scientists go to the US and stay for 10 years is changing , says Mr Jimenez at Novartis .
江慕忠表示:过去那种科学家前往美国呆上10年的模式正在变化。
-
They had a number of key selection criteria , and ultimately the match ended up being right between Google and Novartis .
他们采用了竞争择优的选拔流程,利用一系列关键选择标准,最终发现谷歌和诺华是一对完美拍档。
-
Rufinamide is a new antiepileptic developed by Novartis Company of Switzerland and has finished Phase ⅲ clinical trial .
Rufinamide为瑞士诺华公司新研制的抗癫痫新药,已完成三期临床。
-
Novartis , the Swiss pharmaceuticals group , commercialised artemisinin combination therapy in the 1990s .
上世纪90年代,瑞士制药集团诺华将青蒿素综合疗法商业化。
-
Even that was not adopted widely until its commercialisation by Novartis of Switzerland in the 1990s .
即便是青蒿素,也是直到上世纪90年代被瑞士的诺华(Novartis)商业化以后,才得到了广泛应用。
-
Novartis : The Arts Of Keeping Homeostasis
诺华:保持动态平衡的艺术
-
Novartis defended the decision , saying that it had planned to register the drug long before winning the award .
诺华对这个决定进行了辩护,它说它在获得这个奖的很久之前就打算注册该药了。
-
Chinese companies continue to supply the raw material for the drug to Novartis , and China continues to hold a domestic patent for the therapy .
中国的药厂则继续为诺华提供生产原料。而中国科学家仍拥有该方在中国国内的专利权。
-
Novartis insists that it sells Coartem at cost price and has made no profits out of it .
诺华坚称它一直都是以成本价在销售复方蒿甲醚,并没有从中挣得任何利润。